Gemini Yesodharan, MD
Cardiovascular Disease · Lewiston, MENPI 1366894131
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Edwards Lifesciences at 43.1% of the total. Reporting peaked in 2023 at $2,968 and has fallen 78.6% since, to $634 in 2025. Among cardiovascular disease clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $85.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Abbott$1K
- Abiomed$558
- Terumo Medical Corporation$264
- Penumbra, Inc.$177
- Medtronic$48
What the payments were for
- Travel & lodging$2,50757%
- Food & beverage$1,74740%
- Education$1123%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 17 | $1,880 |
| Abbott | 20 | $1,439 |
| Abiomed | 7 | $558 |
| Terumo Medical Corporation | 4 | $264 |
| Penumbra, Inc. | 2 | $177 |
| Medtronic | 1 | $48 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,366 in reported general payments places this provider in the 90th percentile of 99 cardiovascular disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 69 | $90,127 |
| EliquisApixaban | 50 | $58,006 |
| FarxigaDapagliflozin Propanediol | 16 | $18,223 |
| Metoprolol Succinate | 166 | $2,777 |
| Nifedipine ErNifedipine | 86 | $2,246 |
| Losartan Potassium | 105 | $1,074 |
| Torsemide | 24 | $739 |
| Rosuvastatin Calcium | 31 | $664 |
| Carvedilol | 69 | $533 |
| Ezetimibe | 28 | $478 |
| Chlorthalidone | 32 | $448 |
| Spironolactone | 66 | $371 |
| Atorvastatin Calcium | 42 | $339 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 30 | $308 |
| Potassium Chloride | 20 | $267 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lewiston
- Beata BajgierowiczLewiston$317
- Alan LangburdLewiston$287
- Steven HobsonLewiston$100
- Ronald RosenfeldPerry$51K
- Jonathan HalevyAugusta$22K
- Jeffrey ColnesYork$22K
- Howard GlassWestbrook$13K
- Jaidip ChakravarttiScarborough$8K
- Adam KarpmanPortland$7K
- Marco DiazScarborough$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.